The purpose of this Phase II study is to find out if the drug atomoxetine causes a change in the biomarkers (substances that may indicate the presence of a disease) in the cerebrospinal fluid (CSF) of people diagnosed with mild cognitive impairment (MCI).
|Min Age||Max Age||Gender||Healthy Volunteers|
The purpose of this study is to find out if the drug atomoxetine causes a change in the biomarkers (substances that may indicate the presence of a disease) in the CSF of people diagnosed with MCI. Atomoxetine is a drug for attention deficit hyperactivity disorder that increases levels of norepinephrine, a natural substance in the brain that regulates behavior.
The CSF of participants with MCI who take atomoxetine will be compared to the CSF of those who take a placebo. After 6 months, participants who were taking a placebo will be placed on atomoxetine, and those who received the active study medication will be reassigned to the placebo. After completion of the study, all subjects will be able to receive open-label atomoxetine.
This study will evaluate if atomoxetine is safe and well-tolerated. Researchers will also determine the medication's effect on thinking and behavior, imaging results, and blood biomarkers. The results of this research will help determine if atomoxetine alters signs of inflammation and other biomarkers associated with Alzheimer's disease.
|Map Marker||City||State||Zip Code||Status||Primary Contact|
Geolocation is 33.7980995, -84.3259367
National Institute on Aging
Allan I. Levey, MD, PhD
Margaret L. Walker, PhD